viernes, 27 de diciembre de 2013

Co-Production of NDM-1 and OXA-232 by Klebsiella pneumoniae - Volume 20, Number 1—January 2014 - Emerging Infectious Disease journal - CDC

full-text ►
Co-Production of NDM-1 and OXA-232 by Klebsiella pneumoniae - Volume 20, Number 1—January 2014 - Emerging Infectious Disease journal - CDC

link to Volume 20, Number 1—January 2014

Volume 20, Number 1—January 2014

Letter

Co-Production of NDM-1 and OXA-232 by Klebsiella pneumoniae

To the Editor: New Delhi metallo-β-lactamase 1 (NDM-1) and OXA-48-group β-lactamase have been increasingly reported as carbapenemases responsible for carbapenem resistance in Enterobacteriaceae worldwide (1). However, in the United States, Klebsiella pneumoniae carbapenemase (KPC)–type β-lactamase is the most common carbapenemase amongEnterobacteriaceae, especially Kpneumoniae. Isolates producing NDM-1 were first reported in the United States in 2010 (2), followed by several case reports and most recently a hospital outbreak in Colorado (36). As for OXA-48-group β-lactamase, 2 cases of infection with OXA-48–producing K. pneumoniae were recently reported from Virginia (7). We report K. pneumoniae co-producing NDM-1 and OXA-232, a variant of OXA-48, and Escherichia coli producing NDM-1 that were isolated from the same patient.
A 69-year-old woman was hospitalized in India for subarachnoid hemorrhage in January 2013. Her hospitalization was complicated by unsuccessful coil embolization and subsequent hydrocephalus. A ventriculoperitoneal shunt was inserted, and she was transferred to an acute care hospital in Pittsburgh, Pennsylvania, USA, for further management in February 2013. She underwent reinsertion of the shunt and was discharged to a long-term care facility (LTCF 1). She was readmitted to the same hospital because of fever in March 2013.
A urine culture collected at the time of readmission grew carbapenem-resistant K. pneumoniaeand extended-spectrum β-lactamase–producing E. coli. Although production of KPC-type β-lactamase was initially suspected in K. pneumoniae, the unusually high level of resistance to amikacin (MIC >32 μg/mL) and gentamicin (MIC >8 μg/mL) increased concern for presence of an NDM-1 producer, which is frequently highly resistant to aminoglycosides because of production of 16S rRNA methyltransferase (8). A modified Hodge test showed a positive result for carbapenemase production, and a metallo-β-lactamase Etest (bioMérieux, Marcy l’Etoile, France) showed a positive result for metallo-β-lactamase production.
PCR and sequencing identified NDM-1 and OXA-232, a 5-aa variant of OXA-48 recently reported in K. pneumoniae isolates from India (9). Presence of the gene for 16S rRNA methyltransferase (armA) was also confirmed by PCR and sequencing and accounted for the high-level aminoglycoside resistance. The isolate belonged to sequence type (ST) 14, as determined by multilocus sequence typing, and has been reported to be common among NDM-1–producing K. pneumoniae in Europe (10).
The patient was discharged to LTCF 1 but was readmitted because of recurrent fever. A urine culture collected at this admission grew carbapenem-resistant K. pneumoniae and carbapenem-resistant E. coli. This E. coli isolate belonged to ST95 and was positive for the NDM-1 gene but negative for the OXA-48 group and armA genes. The original extended-spectrum β-lactamase–producing E. coli isolate belonged to ST3865, which is distinct from ST95. Therefore, it is likely that the patient was already colonized by NDM-1–producing E. coli ST95 at the time of the first admission, but this colonization was not detected in a clinical culture at that time. All K. pneumoniae and E. coli isolates remained susceptible to fosfomycin and colistin.
The patient did not receive any antimicrobial drug therapy specific for these isolates because she was deemed to be only colonized with them in the urine. Enhanced contact precautions were also implemented at the time of PCR confirmation of the NDM-1 gene. These precautions included all components of contact precautions (handwashing, gowns, gloves, disinfected/dedicated equipment), and dedicated personnel monitored compliance with these measures around the clock.
The patient was eventually discharged to another long-term care facility (LTCF 2) in April 2013. A point surveillance testing for NDM-1–producing Enterobacteriaceae by using rectal swab specimens was conducted for all inpatients at the acute-care hospital and for all residents of the unit at LTCF 2. Testing did not identify any other patients colonized with NDM-1–producingEnterobacteriaceae.
In transformation and conjugation experiments, transformants carrying the OXA-232 gene were obtained from K. pneumoniae, but those carrying the NDM-1 gene could not be obtained by either method, suggesting that the 2 genes were not located on the same plasmid. For E. coli, transformants and transconjugants carrying the NDM-1 gene were obtained, which indicated that this gene was located on a self-conjugative plasmid.
Detection of NDM-1– or OXA-48-group–producing Enterobacteriaceae, in particular K. pneumoniae, poses a diagnostic challenge in regions to which KPC-producing K. pneumoniae is endemic. In our case, recognition of resistance to multiple aminoglycosides by an automated instrument, which was confirmed to be high level by the disk diffusion method (i.e., no inhibition zone), prompted early detection and implementation of appropriate infection prevention measures. Production of 16S rRNA methyltransferase by KPC-producing K. pneumoniae is extremely rare, and no cases have been identified in the United States. Therefore, we propose that high-level resistance to amikacin and gentamicin can serve as a clue for suspecting potential NDM-1–producing isolates in clinical diagnostic laboratories.
Conversely, Enterobacteriaceae producing OXA-48-group carbapenemase, including variants such as OXA-232, do not have characteristic susceptibility patterns and may easily not be recognized in areas with a high background prevalence of KPC-producing organisms. Therefore, organisms producing OXA-48 or their variants might have already spread in the United States.
Yohei DoiComments to Author , Jessica A. O’Hara, James F. Lando, Ashley M. Querry, Bethany M. Townsend, Anthony W. Pasculle, and Carlene A. Muto
Author affiliations: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA (Y. Doi, J.A. O’Hara, A.M. Querry, B.M. Townsend, A.W. Pasculle, C.A. Muto)Centers for Disease Control and Prevention, assigned to Allegheny County Health Department, Pittsburgh (J.F. Lando)

Acknowledgment

We thank the Antimicrobial Resistance and Characterization Laboratory, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, for assistance in identification of carbapenemase genes, and the Bureau of Epidemiology, Pennsylvania Department of Health, for coordinating active surveillance activities.

References

  1. Nordmann PNaas TPoirel LGlobal spread of carbapenemase-producingEnterobacteriaceae. Emerg Infect Dis2011;17:17918 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  2. Centers for Disease Control and PreventionDetection of Enterobacteriaceae isolates carrying metallo-β-lactamase—United States, 2010. MMWR Morb Mortal Wkly Rep.2010;59:750 .PubMedExternal Web Site Icon
  3. Mochon ABGarner OBHindler JAKrogstad PWard KWLewinski MANew Delhi metallo-β-lactamase (NDM-1)–producing Klebsiella pneumoniae: case report and laboratory detection strategies. J Clin Microbiol2011;49:166770 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  4. Savard PGopinath RZhu WKitchel BRasheed JKTekle TFirst NDM-positiveSalmonella sp. strain identified in the United States. Antimicrob Agents Chemother.2011;55:59578 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  5. Centers for Disease Control and PreventionCarbapenem-resistant Enterobacteriaceaecontaining New Delhi metallo-β-lactamase in two patients—Rhode Island, March 2012.MMWR Morb Mortal Wkly Rep2012;61:4468 .PubMedExternal Web Site Icon
  6. Centers for Disease Control and PreventionNotes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-β-lactamase—Denver, Colorado, 2012. MMWR Morb Mortal Wkly Rep2013;62:108 .PubMedExternal Web Site Icon
  7. Mathers AJHazen KCCarroll JYeh AJCox HLBonomo RAFirst clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the “menace” arrives in the new world. J Clin Microbiol2013;51:6803 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  8. Berçot BPoirel LNordmann PUpdated multiplex polymerase chain reaction for detection of 16S rRNA methylases: high prevalence among NDM-1 producers. Diagn Microbiol Infect Dis2011;71:4425 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  9. Potron ARondinaud EPoirel LBelmonte OBoyer SCamiade SGenetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents2013;41:3259 . DOIExternal Web Site IconPubMedExternal Web Site Icon
  10. Giske CGFroding IHasan CMTurlej-Rogacka AToleman MLivermore DDiverse sequence types of Klebsiella pneumoniae contribute to the dissemination of blaNDM-1 in India, Sweden, and the United Kingdom. Antimicrob Agents Chemother2012;56:27358DOIExternal Web Site IconPubMedExternal Web Site Icon
Suggested citation for this article: Doi Y, O’Hara JA, Lando JN, Querry AM, Townsend BM, Pasculle AW, et al. Co-production of NDM-1 and OXA-232 by Klebsiella pneumoniae [letter]. Emerg Infect Dis [Internet]. 2014 Jan [date cited]. http://dx.doi.org/10.3201/eid2001.130904External Web Site Icon
DOI: 10.3201/eid2001.130904

No hay comentarios:

Publicar un comentario